GO:0070374 positive regulation of ERK1 and ERK2 cascade: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070374 describes any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
• ERK1 (MAPK3) and ERK2 (MAPK1) are terminal kinases of the RAS-RAF-MEK-ERK module, and their positive regulation controls proliferation, differentiation, and survival.
• Dysregulated positive regulation of ERK1/2 is implicated in cancers such as breast cancer and leukemia, as well as in inflammatory and neurological conditions.
• Key upstream regulators include growth factor receptors (EGFR), RAS, RAF, MEK, and scaffolding proteins that assemble the cascade.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect causal roles of individual components in ERK1/2 signaling.
• Functional readouts such as phospho-ERK1/2 immunoblotting, RNA-seq, and proteomics link genotype to pathway output.
Description
The ERK1 and ERK2 cascade is a central mitogen-activated protein kinase (MAPK) signaling module that converts extracellular cues into diverse cellular responses, including proliferation, differentiation, and survival. The Gene Ontology term GO:0070374, positive regulation of ERK1 and ERK2 cascade, captures any process that activates or increases the frequency, rate or extent of signal transduction mediated by this cascade. This term is critical for annotating gene products that enhance ERK1/2 signaling, from growth factor receptors to scaffold proteins and phosphatases that modulate pathway amplitude. Understanding positive regulation of ERK1/2 is essential because excessive or mislocalized ERK activity drives oncogenesis and inflammatory diseases, while insufficient activity contributes to developmental defects and neurodegeneration. Researchers studying this process rely on precise genetic models to determine which components are causally involved in activating the cascade. This article integrates the QuickGO definition with verified PubMed literature to provide a research-grade overview of GO:0070374, its mechanisms, key genes, disease links, and experimental strategies.
positive regulation of ERK1 and ERK2 cascade At A Glance
| GO ID | GO:0070374 |
|---|---|
| GO term | positive regulation of ERK1 and ERK2 cascade |
| Ontology | biological_process |
| Synonym | activation of ERK1 and ERK2 cascade; positive regulation of ERK1/2 cascade; positive regulation of ERK1 and ERK2 signaling pathway; positive regulation of MAPK1 cascade; positive regulation of MAPK3 cascade; upregulation of ERK1 and ERK2 cascade |
| Major function | Enhances signal transduction through the ERK1/2 MAPK pathway, controlling cell proliferation, differentiation, and survival. |
| Upstream activators | Growth factor receptors (e.g., EGFR), RAS GTPases, RAF kinases, MEK1/2, and scaffolding proteins. |
| Downstream effectors | Transcription factors such as ELK1, c-FOS, and c-MYC; cytoplasmic targets regulating cytoskeleton and metabolism. |
| Related diseases | Cancer (breast, leukemia), inflammatory disorders, and neurological conditions. |
What Is GO:0070374?
GO:0070374, positive regulation of ERK1 and ERK2 cascade, is a biological process defined as any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade. In other words, it encompasses all molecular events that enhance the signaling output through the ERK1 (MAPK3) and ERK2 (MAPK1) kinases, including upstream activation of RAS, RAF, and MEK, as well as modulation by scaffolds, phosphatases, and feedback regulators.
Why Is positive regulation of ERK1 and ERK2 cascade Important in Cell Biology?
Positive regulation of the ERK1 and ERK2 cascade is a focal point in cell signaling research because it determines the magnitude and duration of MAPK output, which in turn dictates cell fate decisions such as proliferation versus differentiation. Dysregulation of this process is a hallmark of many cancers, where mutations in upstream regulators like RAS or RAF lead to constitutive ERK1/2 activation. Moreover, ERK1/2 signaling is implicated in immune responses, neuroinflammation, and metabolic disorders, making it a prime target for therapeutic intervention. Understanding how genes positively regulate this cascade is therefore essential for both basic biology and translational medicine.
• Controls fundamental cellular processes including proliferation, differentiation, and survival.
• Constitutive activation of ERK1/2 is a driver in multiple cancers, such as breast cancer and leukemia.
• Modulates immune cell development and responses, as shown in T cell studies.
• Plays a role in neuroinflammation and neurodegenerative diseases like frontotemporal dementia.
• Involved in inflammatory signaling pathways, including those mediated by TRAFs.
• Contributes to ischemic stroke pathology through aberrant pathway activation.
• Serves as a target for kinase inhibitors in cancer therapy, highlighting its clinical relevance.
• Provides a paradigm for understanding MAPK cascade regulation and signal integration.
• Key for interpreting transcriptomic and proteomic data in disease contexts.
• Essential for designing CRISPR-based models to study gene function in signaling.
What Happens During positive regulation of ERK1 and ERK2 cascade?
Receptor Activation and RAS Engagement
In simple terms: Growth factors bind to receptors on the cell surface, turning on a molecular switch called RAS.
Positive regulation begins with ligand binding to receptor tyrosine kinases (RTKs) such as EGFR, leading to receptor autophosphorylation and recruitment of adaptor proteins like GRB2 and SOS. SOS then promotes the exchange of GDP for GTP on RAS, activating it. This step is a key point of positive regulation, as enhanced RTK signaling or mutations in RAS can amplify the cascade. In breast cancer cell lines, modulation of MAPK ERK1/2 has been observed in response to growth factors, underscoring the importance of receptor-level control.
RAF-MEK-ERK Kinase Module
In simple terms: RAS activates a relay of kinases that ultimately switch on ERK1 and ERK2.
Activated RAS recruits RAF kinases (ARAF, BRAF, CRAF) to the membrane, where they are activated by phosphorylation and dimerization. RAF then phosphorylates and activates MEK1/2, which in turn phosphorylates ERK1 and ERK2 on threonine and tyrosine residues. This sequential phosphorylation is the core of the cascade, and positive regulation can occur at any step, for example through scaffolding proteins like KSR that enhance RAF-MEK-ERK assembly. The functional role of ERK1/2 in differentiation was demonstrated in UT-7/GM leukemia cells, where MAPK activity influenced cell fate.
Scaffold and Adaptor Proteins
In simple terms: Scaffold proteins hold the kinases together to make signaling faster and more specific.
Scaffolding proteins such as KSR1, MP1, and β-arrestins physically assemble RAF, MEK, and ERK into complexes, enhancing signal transduction efficiency and specificity. These scaffolds are positive regulators because they increase the frequency and extent of ERK1/2 activation. Additionally, adaptor proteins like TRAFs can modulate MAPK pathways in inflammatory contexts, linking immune signaling to ERK1/2 regulation.
Feedback and Crosstalk Regulation
In simple terms: The pathway has built-in brakes and accelerators that fine-tune the signal.
Positive regulation is balanced by negative feedback loops, such as ERK-mediated phosphorylation of SOS, RAF, and MEK, which dampen signaling. However, positive regulators can override these brakes, for example through phosphatases that remove inhibitory phosphates or through sustained upstream activation. Crosstalk with other pathways, such as the PI3K-AKT pathway, can also enhance ERK1/2 signaling. In ischemic stroke, aberrant pathway activation involving ERK1/2 has been observed, highlighting the importance of context-dependent regulation.
Nuclear Translocation and Transcriptional Output
In simple terms: Once active, ERK1/2 move into the nucleus to turn on genes that control cell behavior.
Activated ERK1/2 translocate to the nucleus, where they phosphorylate transcription factors such as ELK1, c-FOS, and c-MYC, leading to changes in gene expression that drive proliferation, differentiation, or survival. Positive regulation of the cascade thus directly impacts transcriptional programs. In frontotemporal dementia, peripheral immune profiling has revealed alterations in signaling pathways that may involve ERK1/2. Similarly, in chronic rhinosinusitis with nasal polyps, downregulation of EGF and AZGP1 was associated with clinical characteristics, suggesting a link to ERK1/2 signaling.
Key Genes Involved in GO:0070374 positive regulation of ERK1 and ERK2 cascade
The following genes and proteins are central to the positive regulation of the ERK1 and ERK2 cascade, based on their established roles in signaling and disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase that initiates ERK1/2 signaling upon ligand binding | Target in cancer; mutations affect pathway activation |
| KRAS | Small GTPase that activates RAF kinases | Oncogene frequently mutated in cancers; key positive regulator |
| BRAF | Serine/threonine kinase that phosphorylates MEK | Mutated in melanoma and other cancers; drug target |
| MAP2K1 (MEK1) | Dual-specificity kinase that phosphorylates ERK1/2 | Central node; mutations cause developmental disorders |
| MAPK3 (ERK1) | Terminal kinase of the cascade; regulates transcription and cytoskeleton | Effector of positive regulation; knockout models available |
| MAPK1 (ERK2) | Terminal kinase; often predominant in ERK1/2 signaling | Essential for development; knockout is lethal |
| KSR1 | Scaffold protein that enhances RAF-MEK-ERK assembly | Positive regulator; modulates pathway efficiency |
| TRAF6 | E3 ubiquitin ligase that can activate MAPK pathways | Links immune signaling to ERK1/2; inflammation |
| LIF | Cytokine that can activate ERK1/2 in stromal cells | Implicated in tumor budding in breast cancer |
| ULK1 | Autophagy kinase that regulates T cell development and MAPK signaling | Modulates ERK1/2 in immune cells |
| DUSP6 | Phosphatase that negatively regulates ERK1/2 | Feedback regulator; its inhibition enhances ERK1/2 output |
| ELK1 | Transcription factor phosphorylated by ERK1/2 | Readout of nuclear ERK activity |
| FOS | Immediate early gene induced by ERK1/2 | Marker of pathway activation |
| MYC | Transcription factor stabilized by ERK1/2 signaling | Drives proliferation; oncogene |
| AZGP1 | Secreted protein linked to EGF signaling | Downregulated in chronic rhinosinusitis; potential ERK1/2 crosstalk |
| VDR | Vitamin D receptor that modulates MAPK ERK1/2 | Breast cancer cell lines show VDR-dependent ERK modulation |
| GRB2 | Adaptor protein linking RTKs to RAS | Essential for RTK-mediated ERK1/2 activation |
How Is positive regulation of ERK1 and ERK2 cascade Regulated?
Positive regulation of the ERK1 and ERK2 cascade is itself tightly regulated by multiple mechanisms. Upstream, growth factor availability and receptor expression levels determine signal initiation. Intracellularly, scaffold proteins like KSR1 enhance pathway efficiency, while phosphatases such as DUSP6 provide negative feedback. Crosstalk with other signaling pathways, including PI3K-AKT and Wnt, can modulate ERK1/2 activity. In immune cells, ULK1 has been shown to regulate T cell development and response to Listeria monocytogenes, partly through MAPK signaling. Additionally, inflammatory mediators like TRAFs can activate ERK1/2, linking immune signaling to this cascade. In disease states such as ischemic stroke, aberrant activation of ERK1/2 pathways has been observed, suggesting that regulatory mechanisms are disrupted.
positive regulation of ERK1 and ERK2 cascade and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| KRAS | Cancer (pancreatic, lung, colorectal) | Knock-in of KRAS G12D in cell lines; ERK1/2 phosphorylation readout |
| BRAF | Melanoma, thyroid cancer | Point mutation (V600E) knock-in; drug sensitivity assays |
| EGFR | Breast cancer, chronic rhinosinusitis | Knockout or overexpression in breast cancer cell lines; EGF stimulation |
| LIF | Triple-negative breast cancer tumor budding | Knockdown in stromal cells; co-culture with tumor cells |
| ULK1 | T cell development and immune response | Knockout in T cells; Listeria infection model |
Cancer
Constitutive activation of the ERK1/2 cascade is a hallmark of many cancers. Mutations in upstream regulators such as KRAS and BRAF lead to sustained ERK1/2 signaling, promoting uncontrolled proliferation and survival. In breast cancer cell lines, modulation of MAPK ERK1/2 has been observed in response to vitamin D receptor status, indicating that positive regulation can be influenced by nuclear receptors. In leukemia, ERK1/2 activity influences cell fate determination toward erythroid or megakaryocytic lineages, highlighting its role in differentiation and potential therapeutic targeting. In triple-negative breast cancer, stromal transcriptomics identified LIF as a key effector in high tumor budding, potentially acting through ERK1/2 signaling.
Neurological and Inflammatory Disorders
Dysregulated ERK1/2 signaling contributes to neuroinflammation and neurodegeneration. In frontotemporal dementia, peripheral immune profiling revealed alterations that may involve MAPK pathways. In ischemic stroke, comprehensive immune infiltration analysis showed aberrant pathway activation, including ERK1/2, suggesting a role in post-stroke inflammation. Chronic rhinosinusitis with nasal polyps has been associated with downregulation of EGF and AZGP1, which may affect ERK1/2 signaling and contribute to disease pathology. These findings underscore the importance of positive regulation of ERK1/2 in inflammatory and neurological conditions.
Immune Regulation
ERK1/2 signaling is critical for immune cell development and function. ULK1 regulates T cell development and response to Listeria monocytogenes, partly through modulation of MAPK pathways. TRAF proteins, which mediate inflammatory responses, can activate ERK1/2, linking innate immune signaling to this cascade. Thus, positive regulation of ERK1/2 is integral to both adaptive and innate immunity.
From positive regulation of ERK1 and ERK2 cascade-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate ERK1/2 cascade? | CRISPR knockout of gene X followed by phospho-ERK1/2 immunoblotting |
| Does a specific mutation in gene X alter ERK1/2 activation? | Point mutation knock-in (e.g., kinase-dead or constitutively active) in cell lines |
| Does gene X require a tag for interaction studies? | Tagged knock-in (e.g., GFP or HA) for co-immunoprecipitation and imaging |
| Does overexpression of gene X enhance ERK1/2 signaling? | Overexpression via lentiviral transduction or inducible systems |
| Which genes regulate ERK1/2 in a disease context? | CRISPR library screening with phospho-ERK1/2 as readout |
| Does gene X affect ERK1/2-dependent transcription? | Knockout or overexpression combined with RNA-seq and ELK1 reporter assays |
How to Study the positive regulation of ERK1 and ERK2 cascade Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-ERK1/2 immunoblotting | Levels of activated ERK1/2 | Quantifying pathway activation after genetic or pharmacological perturbation |
| Immunofluorescence | Subcellular localization and intensity of phospho-ERK1/2 | Visualizing activation in single cells and tissues |
| RNA-seq | Transcriptional changes downstream of ERK1/2 | Identifying gene expression signatures associated with pathway activity |
| Proteomics | Protein abundance and post-translational modifications | Discovering novel regulators and effectors of ERK1/2 |
| CRISPR knockout screens | Genes required for ERK1/2 activation | Systematic discovery of positive regulators |
| FRET biosensors | Real-time ERK1/2 activity dynamics | Live-cell imaging of signaling kinetics |
| Co-immunoprecipitation | Protein-protein interactions | Mapping scaffold and adaptor complexes in the cascade |
| Reporter assays (ELK1-luciferase) | Transcriptional output of ERK1/2 | Measuring functional consequences of pathway modulation |
Phospho-ERK1/2 Immunoblotting and Immunofluorescence
The most direct method to assess positive regulation of ERK1/2 is to measure phosphorylation levels of ERK1 (Thr202/Tyr204) and ERK2 (Thr185/Tyr187) using immunoblotting or immunofluorescence. These techniques quantify pathway activation in response to stimuli or genetic perturbations. They are widely used in cancer cell lines and primary cells to evaluate the impact of candidate regulators.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can reveal downstream transcriptional and proteomic changes driven by ERK1/2 activation. For example, in chronic rhinosinusitis, transcriptomic analysis identified EGF and AZGP1 as associated with clinical characteristics, potentially through ERK1/2 signaling. In triple-negative breast cancer, stromal transcriptomics uncovered LIF as a key effector. These approaches help identify novel positive regulators and effectors of the cascade.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens coupled with phospho-ERK1/2 readouts (e.g., flow cytometry or imaging) can systematically identify positive regulators of the cascade. Such screens have been instrumental in mapping signaling networks and are applicable to various cell types. Bioinformatics analysis of screen hits can reveal enriched pathways and potential drug targets.
Live-Cell Imaging and Biosensors
Genetically encoded FRET-based biosensors (e.g., EKAR) allow real-time monitoring of ERK1/2 activity in living cells. These tools provide spatiotemporal dynamics of positive regulation, revealing how scaffolds and feedback loops shape signaling. They are particularly useful for studying rapid signaling events and subcellular localization.
How CRISPR Can Be Used to Study GO:0070374 positive regulation of ERK1 and ERK2 cascade
Knockout
CRISPR knockout of candidate genes is a powerful approach to determine whether they are required for positive regulation of ERK1/2. By generating loss-of-function cell lines, researchers can measure changes in phospho-ERK1/2 levels and downstream transcriptional outputs. For example, knocking out EGFR or KRAS in cancer cell lines can abolish ERK1/2 activation and reduce proliferation. Knockout models are also useful for validating hits from CRISPR screens.
Point Mutation
Point mutation knock-in allows precise modeling of disease-associated or functional variants. For instance, introducing the BRAF V600E mutation or KRAS G12D into cell lines can constitutively activate ERK1/2, mimicking oncogenic signaling. Conversely, kinase-dead mutations can reveal whether catalytic activity is required for positive regulation. These models are essential for drug sensitivity testing and understanding allele-specific effects.
Knock-in
Knock-in of tagged versions of ERK1/2 or their regulators (e.g., GFP, HA, or BirA tags) enables visualization, interaction studies, and proximity labeling. Tagged knock-in cell lines preserve endogenous expression and regulation, providing more physiologically relevant insights than overexpression. They are particularly useful for studying scaffold dynamics and subcellular localization.
Overexpression
Overexpression of wild-type or mutant genes can test sufficiency for ERK1/2 activation. For example, overexpressing constitutively active MEK1 or RAF1 leads to robust ERK1/2 phosphorylation and downstream responses. Overexpression models are also valuable for studying gain-of-function mutations and for screening inhibitors. However, results should be interpreted with caution due to non-physiological expression levels.
How EDITGENE Supports positive regulation of ERK1 and ERK2 cascade Research
Researchers studying positive regulation of ERK1 and ERK2 cascade-related genes often need to determine whether a candidate gene is causally involved in activating the pathway. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation and mechanistic studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of ERK1 and ERK2 cascade research.
Frequently Asked Questions About positive regulation of ERK1 and ERK2 cascade
What is GO:0070374?
GO:0070374 is the Gene Ontology term for positive regulation of ERK1 and ERK2 cascade, defined as any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.
What genes are involved in positive regulation of ERK1 and ERK2 cascade?
Key genes include EGFR, KRAS, BRAF, MAP2K1 (MEK1), MAPK3 (ERK1), MAPK1 (ERK2), KSR1, and TRAF6, among others.
How is ERK1/2 signaling activated?
ERK1/2 signaling is activated by growth factor receptors that trigger RAS-RAF-MEK-ERK phosphorylation, often enhanced by scaffold proteins.
What diseases are associated with ERK1/2 dysregulation?
Cancers such as breast cancer and leukemia, as well as inflammatory and neurological disorders like frontotemporal dementia and ischemic stroke, are linked to ERK1/2 dysregulation.
What methods are used to study positive regulation of ERK1/2?
Common methods include phospho-ERK1/2 immunoblotting, immunofluorescence, RNA-seq, proteomics, CRISPR screens, and FRET biosensors.
Can CRISPR be used to study ERK1/2 regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to dissect gene function in ERK1/2 signaling.
What is the role of ULK1 in ERK1/2 signaling?
ULK1 regulates T cell development and response to Listeria monocytogenes, partly through modulation of MAPK pathways including ERK1/2.
How does LIF affect ERK1/2 in cancer?
In triple-negative breast cancer, stromal LIF has been identified as a key effector in high tumor budding, potentially acting through ERK1/2 signaling.
What is the link between ERK1/2 and chronic rhinosinusitis?
Downregulation of EGF and AZGP1 in chronic rhinosinusitis with nasal polyps may affect ERK1/2 signaling, contributing to disease characteristics.
What EDITGENE services are available for ERK1/2 research?
EDITGENE offers CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services tailored to ERK1/2 pathway studies.
Conclusion
GO:0070374, positive regulation of ERK1 and ERK2 cascade, is a fundamental biological process that governs cellular responses to growth factors and stress. Its dysregulation is implicated in cancer, inflammatory diseases, and neurological disorders, making it a critical area of research. By leveraging CRISPR-based models and advanced functional genomics, researchers can dissect the precise roles of individual genes in activating this cascade. EDITGENE provides the tools and expertise to accelerate these discoveries, from custom cell line generation to high-throughput screening and bioinformatics support.
References
- 1. Gamez N et al.. 2026. Peripheral immune profiling in frontotemporal dementia.. Brain Commun 8(2):fcag089 PMID: 41924698
- 2. Uchida M et al.. 2001. A functional role of mitogen-activated protein kinases, erk1 and erk2, in the differentiation of a human leukemia cell line, UT-7/GM: a possible key factor for cell fate determination toward erythroid and megakaryocytic lineages.. Int J Hematol 73(1):78-83 PMID: 11372759
- 3. Cordes T et al.. 2006. Modulation of MAPK ERK1 and ERK2 in VDR-positive and -negative breast cancer cell lines.. Anticancer Res 26(4A):2749-53 PMID: 16886687
- 4. Dhillon B et al.. 2019. The Evolving Role of TRAFs in Mediating Inflammatory Responses.. Front Immunol 10:104 PMID: 30778351
- 5. Phankeaw P et al.. 2025. Stromal transcriptomics uncover LIF as a key effector in high tumor budding triple-negative breast cancer.. Sci Rep 15(1):45309 PMID: 41290930
- 6. Jin P et al.. 2023. Down Regulation of EGF and AZGP1 Were Associated with Clinical Characteristics in Chronic Rhinosinusitis with Nasal Polyps: An Observation Study.. J Inflamm Res 16:4885-4898 PMID: 37920240
- 7. Xu Y et al.. 2024. Ulk1 regulates T cell development and response to Listeria monocytogenes stimulation.. J Leukoc Biol 117(1) PMID: 39183699
- 8. Liu R et al.. 2021. Comprehensive Landscape of Immune Infiltration and Aberrant Pathway Activation in Ischemic Stroke.. Front Immunol 12:766724 PMID: 35140708
